patent.fyi
Applications  /  US 2026/0355295
United States Patent Application Publication

US 2026/0355295 A1

Published
Nov 12, 2026
Filed
Jun 11, 2026
Earliest date on the face
Dec 11, 2023
Classification
A61K 38/4893
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Recombinant single-chain neurotoxin

What ifWhat if the composition contains a recombinant single-chain neurotoxin without chimeric domains?
Claim language“a chimeric botulinum neurotoxin”

A recombinant expression system produces the heavy and light chains of a single serotype. The chains assemble into a single-chain protein during purification. This protein retains the binding and catalytic functions without requiring domain swapping between different serotypes.

1.2Buffering with citrate salts

What ifWhat if the composition uses citrate salts for buffering without L-histidine?
Claim language“L-histidine”

Sodium citrate and citric acid maintain the pH between 5.5 and 6.5. The citrate ions chelate trace metals that catalyze oxidation. This buffering system stabilizes the protein structure during lyophilization.

1.3Adjusting ph with hydrochloric acid

What ifWhat if the pH is adjusted with hydrochloric acid without histidine-HCl?
Claim language“histidine-HCl”

Aqueous hydrochloric acid lowers the pH of the protein solution to the target range. The chloride ions provide ionic strength without adding additional buffering capacity. This approach requires careful titration to prevent localized denaturation.

1.2Amino acid substitution

What ifWhat if the composition uses L-arginine without L-histidine?
Claim language“L-histidine”

L-arginine suppresses protein aggregation during lyophilization by interacting with exposed hydrophobic patches. The guanidinium group forms hydrogen bonds with the protein surface. This amino acid maintains protein solubility at high concentrations.

1.3Buffering with phosphate salts

What ifWhat if the composition uses phosphate salts without histidine-HCl?
Claim language“histidine-HCl”

Sodium phosphate monobasic and dibasic maintain the pH between 6.0 and 7.0. The phosphate buffer capacity prevents pH shifts during storage. This system requires exclusion of divalent cations to prevent precipitation.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Solid protein stabilisation for agricultural biocontrol agents

A solid powder formulation contains a chimeric protein toxin derived from bacterial pathogens, L-histidine, and histidine-hydrochloride. The mixture is lyophilised into tablets for field application against insect pests. The histidine buffer maintains pH stability during storage under high ambient temperatures.

Component substitution

Substituting trehalose for sucrose stabiliser

The solid composition replaces sucrose with trehalose as the primary disaccharide stabiliser. Trehalose forms a glassy matrix around the chimeric neurotoxin during drying. This substitution maintains protein integrity while altering the dissolution profile in aqueous reconstitution.

Replacing histidine-hydrochloride with phosphate buffer

The solid composition substitutes sodium phosphate dibasic and monobasic for histidine-hydrochloride. The phosphate salts maintain the target pH range during reconstitution and storage. This change alters the ionic strength profile while preserving the chimeric toxin's structural stability.

Parameter or scale variation

Microgram scale manufacturing for veterinary dosing

The formulation process scales up to produce batches containing microgram quantities of chimeric neurotoxin. L-histidine and histidine-hydrochloride are mixed at fixed ratios in large-volume stainless steel vessels. The resulting powder is filled into multi-dose vials for veterinary injection applications.

Combination with existing systems

Integrated spray drying production line

The liquid formulation containing the chimeric toxin and histidine buffer is fed into a spray dryer. Hot air atomises the solution into fine droplets that dry into solid particles. The collected powder is immediately sealed under nitrogen in moisture-barrier containers.

Automated or data-driven variant

Sensor-controlled lyophilisation cycle optimisation

Temperature and pressure sensors monitor the freezing and drying stages of the lyophilisation process. A control algorithm adjusts vacuum levels and shelf temperatures based on real-time moisture readings. The system terminates the cycle when residual moisture falls below a set threshold.

Specific version of a part

Inactivated toxin derivative

Chemical modification of the active site zinc-binding motif eliminates enzymatic cleavage of SNARE proteins. The modified toxin retains receptor binding affinity but cannot cause paralysis. This derivative serves as an immunogen or binding inhibitor.

Recombinant chimeric neurotoxin

The heavy chain binding domain from serotype A is fused to the catalytic domain from serotype B. A flexible linker peptide connects the domains. The chimeric protein is expressed in mammalian cells and purified by ion exchange chromatography.

Lyophilized l-histidine

L-histidine is dissolved in water at a concentration of 10 to 50 millimolar. The solution is frozen at minus forty degrees Celsius. Primary drying occurs under vacuum at minus twenty degrees Celsius for twenty hours.

Histidine hydrochloride monohydrate

Histidine hydrochloride monohydrate is added to the protein solution at a concentration of 5 to 20 millimolar. The salt provides chloride ions for ionic strength. The pH is adjusted to 5.5 to 6.5.

Chimeric neurotoxin complex

The chimeric neurotoxin is associated with non-toxic non-hemagglutinin proteins. The complex forms a high molecular weight aggregate. The complex protects the neurotoxin from enzymatic degradation in the gastrointestinal tract.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2023/0137216 A1
Published
May 4, 2023
Filed
Mar 15, 2021
Class
A61K 47/22
Document BUS 11,752,209 B2
Published
Sep 12, 2023
Filed
Nov 2, 2022
Class
A61K 39/39591
Claim 1
Document A
Document B
1.1(a) a chimeric botulinum neurotoxin (BoNT);
1.2(b) L-histidine; and
A histidine buffer consists of histidine (i.e., a weak base) and an acid addition salt thereof.
A · US 2023/0137216 A1 · ¶ 27
By way of example: A histidine “buffering agent” is the free amino acid, histidine.
B · US 11,752,209 B2 · ¶ 78
1.3(c) histidine-HCl.
In the case of an histidine buffer system, this means mixing histidine with an imidazolium form of histidine (e.g. histidine hydrochloride).
B · US 11,752,209 B2 · ¶ 333

An empty cell means only that no passage was reproduced there.

Statements in these documents
However, the degradation of the polysorbate surfactant has been an issue of concern in the pharmaceutical industry over the past decade.
A · US 2023/0137216 A1 · ¶ 5
It is therefore crucial to maintain intact polysorbates in drug products.
A · US 2023/0137216 A1 · ¶ 5
Though the aforementioned commercial formulation of Adalimumab is stable (at least to some extent), the relevant antibody may be unstable over prolonged periods or under stressed conditions, thus precluding prolonged storage of said formulations.
B · US 11,752,209 B2 · ¶ 7
Cite aspatent.fyi, US 2026/0355295 A1, claim 1, first published 2026-11-19T14:30:38-05:00, https://patent.fyi/US20260355295/, SHA-256 3895e15aada184324e92f6517280d81751474b5983887682e756241a1228d7f7
First published
Permanent addresshttps://patent.fyi/US20260355295/
Content fingerprint (SHA-256)3895e15aada184324e92f6517280d81751474b5983887682e756241a1228d7f7
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi